Skip to search formSkip to main contentSkip to account menu

edotecarin

Known as: 12-beta-D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy-13-glucopyranosyl-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)dione, 6-N-(1-hydroxymethyla-2-hydroxy)ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)-5H-indolo[2,3-a]-pyrrolol[3,4-c]-carbazole-5,7(6H)-dione 
A synthetic indolocarbazole with antineoplastic activity. Edotecarin inhibits the enzyme topoisomerase I through stabilization of the DNA-enzyme… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Carbazoles

Narrower (2)

J 107088PHA-782615
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Edotecarin.
  • W. Denny
  • IDrugs : the investigational drugs journal
  • 2020
  • Corpus ID: 241179323
Banyu Pharmaceutical Co Ltd and Pfizer Inc (formerly Pharmacia Corp) are developing edotecarin, an indolocarbazole topoisomerase… 
2012
2012
Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety.
2010
2010
A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors
Edotecarin (J-107088), a novel inhibitor of topoisomerase I has an additive effect on colon cell lines (HCT-116) when combined… 
2009
2009
Synthesis and biological activities of topoisomerase I inhibitors, 6-arylmethylamino analogues of edotecarin.
The replacement of 1,3-dihydroxy-2-propylamino moiety at the N6-position of edotecarin (1) by arylmethylamino groups yielded a… 
2008
2008
Synthesis, Biological Evaluation, and Molecular Modeling Studies of Rebeccamycin Analogues Modified in the Carbohydrate Moiety
A new series of indolocarbazole glycosides containing disaccharides were synthesized and their in vitro antiproliferative… 
2006
2006
Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors
Purpose: Edotecarin (J-107088) is a potent indolocarbazole topoisomerase I inhibitor which is structurally distinct from the… 
2006
2006
Antitumor Efficacy of Edotecarin as a Single Agent and in Combination with Chemotherapy Agents in a Xenograft Model
The novel indolocarbazole edotecarin (J-107088, formerly ED-749) differs from other topoisomerase I inhibitors both… 
2006
2006
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors
PurposeTo assess the maximum tolerated dose, safety, and pharmacokinetic (PK) profile of escalating doses of the novel… 
2006
2006
Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report.
We describe the response to a new chemotherapy agent, topoisomerase I inhibitor edotecarin in an 18-year-old woman with recurring… 
2005
2005
Pharmacokinetics (PK) of edotecarin (J-107088), a topoisomerase I inhibitor, in patients with metastatic breast cancer (mBC) or glioblastoma multiforme (GBM)
2073 Background: Edotecarin is an indolocarbazole topoisomerase I inhibitor currently under clinical development for cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)